Intravitreal bevacizumab for choroidal neovascularization secondary to laser photocoagulation for central serous chorioretinopathy.

Related Articles

Intravitreal bevacizumab for choroidal neovascularization secondary to laser photocoagulation for central serous chorioretinopathy.

Eur J Ophthalmol. 2012 May-Jun;22(3):488-91

Authors: Pikkel J, Rumelt S

Abstract
PURPOSE: Choroidal neovascularization (CNV) is a rare complication after laser photocoagulation for disorders such as central serous chorioretinopathy (CSC).
METHODS: We report 2 patients who developed CNV after laser treatment for persistent CSC and were treated by 3 1.25-mg intravitreal injections of bevacizumab in 1-month intervals.
RESULTS: In both patients, best-corrected visual acuity improved from 20/120 to 20/80 and from counting fingers at 3 feet to 20/100 over 12 months of follow-up.
CONCLUSIONS: The favorable outcome suggests that intravitreal injection of bevacizumab may be beneficial for patients who develop CNV after laser photocoagulation. The favorable outcome may be related to the limited pathology.

PMID: 21928270 [PubMed - indexed for MEDLINE]

SEE HERE CLICK HERE